{"id":5661,"date":"2021-12-17T11:02:52","date_gmt":"2021-12-17T11:02:52","guid":{"rendered":"https:\/\/www.cubasupport.ie\/latest\/?p=5661"},"modified":"2021-12-17T11:04:33","modified_gmt":"2021-12-17T11:04:33","slug":"cuba-results-of-new-alzheimers-drug-revealed","status":"publish","type":"post","link":"https:\/\/www.cubasupport.ie\/latest\/cuba-results-of-new-alzheimers-drug-revealed\/","title":{"rendered":"Cuba: results of new Alzheimer\u2019s drug revealed"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\">The drug is the result of studies carried out by the Center for Molecular Immunology (CIM) in collaboration with other BioCubaFarma institutions.<\/h2>\n\n\n\n<figure class=\"wp-block-image size-full\"><img data-recalc-dims=\"1\" loading=\"lazy\" decoding=\"async\" width=\"747\" height=\"534\" src=\"https:\/\/i0.wp.com\/www.cubasupport.ie\/latest\/wp-content\/uploads\/laboratorista-en-Centro-de-Inmunologia-Molecular-CIM-750x563-1-750x536-1.jpeg?resize=747%2C534&#038;ssl=1\" alt=\"\" class=\"wp-image-5662\" srcset=\"https:\/\/i0.wp.com\/www.cubasupport.ie\/latest\/wp-content\/uploads\/laboratorista-en-Centro-de-Inmunologia-Molecular-CIM-750x563-1-750x536-1.jpeg?w=750&amp;ssl=1 750w, https:\/\/i0.wp.com\/www.cubasupport.ie\/latest\/wp-content\/uploads\/laboratorista-en-Centro-de-Inmunologia-Molecular-CIM-750x563-1-750x536-1.jpeg?resize=300%2C214&amp;ssl=1 300w, https:\/\/i0.wp.com\/www.cubasupport.ie\/latest\/wp-content\/uploads\/laboratorista-en-Centro-de-Inmunologia-Molecular-CIM-750x563-1-750x536-1.jpeg?resize=120%2C85&amp;ssl=1 120w\" sizes=\"auto, (max-width: 747px) 100vw, 747px\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Cuban scientists revealed the results of the phase II-III clinical trial of the Cuban product NeuroEpo in patients with mild\/moderate Alzheimer\u2019s disease, and they are encouraging, according to the&nbsp;<a href=\"http:\/\/www.cubadebate.cu\/noticias\/2021\/12\/13\/neuroepo-mas-que-gotas-de-esperanza-frente-a-la-enfermedad-del-alzheimer\/?fbclid=IwAR0Rl709y6BTtZIIAPU-xR--F5Iv7F-vdugha74iXw62BxS7cxXy5JdT5u4\" target=\"_blank\" rel=\"noreferrer noopener\">information<\/a>&nbsp;published on the Cubadebate website.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The drug is the result of studies carried out by the Center for Molecular Immunology (CIM) in collaboration with other BioCubaFarma institutions to achieve a nasal formulation of recombinant EPO with a low content of sialic acid, an isoform with a composition similar to natural EPO produced in the central nervous system.<\/p>\n\n\n\n<figure class=\"wp-block-embed aligncenter is-type-rich is-provider-twitter wp-block-embed-twitter\"><div class=\"wp-block-embed__wrapper\">\nhttps:\/\/twitter.com\/PresidenciaCuba\/status\/1470711132927270912?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1470711132927270912%7Ctwgr%5E%7Ctwcon%5Es1_c10&#038;ref_url=https%3A%2F%2Foncubanews.com%2Fen%2Fcuba%2Fscience-cuba%2Fscience-in-cuba%2Fcuba-results-of-new-alzheimers-drug-revealed%2F\n<\/div><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The principal researcher of the clinical trial, Dr. Saily Sosa P\u00e9rez, pointed out that \u201cwe are in the presence of an achievement of Cuban science that will allow the treatment, with our product, of a traumatic disease, both for patients and their families, especially those who must take care of them, who are usually one or two members of the family.\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Dr. Sosa P\u00e9rez, who leads a service for attention to memory disorders, explained that in the world there are only six medications to alleviate the effects of the disease, and all are extremely expensive (treatment for a year can exceed up to $80,000).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The researchers, cited by the media, pointed out that the application of isoforms of this erythropoietin (EPO) could restore cerebral homeostasis, acting on neurons and astrocytes; and that novel EPO formulations, with great selectivity on the brain, could be used to treat neurodegenerative diseases and slow their progression.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">On the data collected during clinical trial II-III during intranasal administration of the product, the experts established that treatment with NeuroEPO for 48 weeks was safe and well tolerated (there were no serious adverse events), that many of the patients showed a reduction in the progression of cognitive impairment and secondary variables also improved.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The study \u2014 randomised, double-blind, placebo-controlled and adaptive design \u2014 also showed signs of improvement in cerebral perfusion in the parietal-temporal region, and that 72% of the treated patients stabilised the global values \u200b\u200bof the electroencephalogram (EEG), among other results.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">It also emerged that the application of the product is being evaluated for the treatment of other diseases, such as ataxia, Parkinson\u2019s, ischemic brain accidents, and the sequelae of COVID-19.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Alzheimer\u2019s disease is considered the leading cause of disability in the elderly in Cuba, whose population is currently experiencing accelerated aging (at the end of 2020, 21.3% were 60 years old and over).<\/p>\n\n\n\n<hr class=\"wp-block-separator is-style-wide\"\/>\n\n\n\n<p class=\"wp-block-paragraph\">source: OnCuba<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The drug is the result of studies carried out by the Center for Molecular Immunology (CIM) in collaboration with other BioCubaFarma institutions. Cuban scientists revealed<a class=\"moretag\" href=\"https:\/\/www.cubasupport.ie\/latest\/cuba-results-of-new-alzheimers-drug-revealed\/\"> [&#8230;]<\/a><\/p>\n","protected":false},"author":3,"featured_media":5662,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_hide_featured_image":false,"_jetpack_featured_image_duplicate_dismissed":0,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[8,43],"tags":[],"class_list":["post-5661","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cuba","category-featured"],"jetpack_publicize_connections":[],"jetpack-related-posts":[{"id":7747,"url":"https:\/\/www.cubasupport.ie\/latest\/the-battle-against-alzheimers-disease-is-a-priority-for-cuba\/","url_meta":{"origin":5661,"position":0},"title":"The battle against Alzheimer&#8217;s disease is a priority for Cuba.","author":"Editorial Team","date":"October 11, 2022","format":false,"excerpt":"Alzheimer's disease is the most common form of dementia (a syndrome generally of a chronic or progressive nature, characterized by the deterioration of cognitive function). According to the World Health Organization (WHO), it is estimated that this type of dementia represents between 60% and 70% of overall cases.","rel":"","context":"In &quot;Cuba&quot;","block_context":{"text":"Cuba","link":"https:\/\/www.cubasupport.ie\/latest\/category\/cuba\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/www.cubasupport.ie\/latest\/wp-content\/uploads\/Screenshot-2022-10-11-at-22.50.24.png?fit=583%2C402&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.cubasupport.ie\/latest\/wp-content\/uploads\/Screenshot-2022-10-11-at-22.50.24.png?fit=583%2C402&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/www.cubasupport.ie\/latest\/wp-content\/uploads\/Screenshot-2022-10-11-at-22.50.24.png?fit=583%2C402&ssl=1&resize=525%2C300 1.5x"},"classes":[]},{"id":7585,"url":"https:\/\/www.cubasupport.ie\/latest\/cuba-strides-ahead-in-research-of-new-alzheimers-treatment\/","url_meta":{"origin":5661,"position":1},"title":"Cuba strides ahead in research of new Alzheimer\u2019s treatment","author":"Editorial Team","date":"September 21, 2022","format":false,"excerpt":"Cuban scientists have announced the next stage of research on NeuralCIM, a neuroprotective drug for Alzheimer\u2019s disease and other forms of dementia. Cuba continues to make major strides in medical research and development in spite of the US-imposed blockade and the challenges it poses, including in the case of the\u00a0Matanzas\u00a0fire.\u2026","rel":"","context":"In &quot;Featured&quot;","block_context":{"text":"Featured","link":"https:\/\/www.cubasupport.ie\/latest\/category\/news\/featured\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/www.cubasupport.ie\/latest\/wp-content\/uploads\/older-people-1.jpeg?fit=700%2C457&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.cubasupport.ie\/latest\/wp-content\/uploads\/older-people-1.jpeg?fit=700%2C457&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/www.cubasupport.ie\/latest\/wp-content\/uploads\/older-people-1.jpeg?fit=700%2C457&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/www.cubasupport.ie\/latest\/wp-content\/uploads\/older-people-1.jpeg?fit=700%2C457&ssl=1&resize=700%2C400 2x"},"classes":[]},{"id":7861,"url":"https:\/\/www.cubasupport.ie\/latest\/cubans-trust-vaccines-and-how-theyre-helping-vaccinate-the-world\/","url_meta":{"origin":5661,"position":2},"title":"Cubans trust vaccines and how they\u2019re helping vaccinate the\u00a0world","author":"Editorial Team","date":"November 20, 2022","format":false,"excerpt":"Cuba continues to be at the forefront in the development of medical treatments for the benefit of mankind, especially in diseases such as Alzheimer's and Parkinson's disease. It is also willing to transfer its technologies to other nations on a non-profit basis, as has always been the motto of the\u2026","rel":"","context":"In &quot;Cuba&quot;","block_context":{"text":"Cuba","link":"https:\/\/www.cubasupport.ie\/latest\/category\/cuba\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/www.cubasupport.ie\/latest\/wp-content\/uploads\/Screenshot-2022-11-19-at-19.13.40.png?fit=394%2C259&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":5394,"url":"https:\/\/www.cubasupport.ie\/latest\/cuba-has-a-drug-against-alzheimers-disease\/","url_meta":{"origin":5661,"position":3},"title":"Cuba has a drug against Alzheimer&#8217;s disease","author":"Editorial Team","date":"November 1, 2021","format":false,"excerpt":"Cuba's Center for State Control of Medicines, Equipment and Medical Devices (CECMED) evaluates for registration the drug called NeuroEpo, an innovative product against Alzheimer's Disease. Scientists from Cuba have demonstrated its safety after long years of pharmaceutical, toxicological, efficacy in animals and diseases studies, and the clinical trial was conducted\u2026","rel":"","context":"In &quot;Cuba&quot;","block_context":{"text":"Cuba","link":"https:\/\/www.cubasupport.ie\/latest\/category\/cuba\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/www.cubasupport.ie\/latest\/wp-content\/uploads\/older-people-cuba.jpeg?fit=600%2C883&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.cubasupport.ie\/latest\/wp-content\/uploads\/older-people-cuba.jpeg?fit=600%2C883&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/www.cubasupport.ie\/latest\/wp-content\/uploads\/older-people-cuba.jpeg?fit=600%2C883&ssl=1&resize=525%2C300 1.5x"},"classes":[]},{"id":7077,"url":"https:\/\/www.cubasupport.ie\/latest\/cuban-vaccine-against-lung-cancer-makes-its-way-in-the-united-states\/","url_meta":{"origin":5661,"position":4},"title":"Cuban vaccine against lung cancer makes its way in the United States","author":"Editorial Team","date":"August 8, 2022","format":false,"excerpt":"Cimavax-EGF, a Cuban therapeutic vaccine against lung cancer, conquers the scientific community and the population of the United States based on the achievements compiled in studies carried out. Cimavax-EGF, a Cuban therapeutic vaccine against lung cancer, conquers the scientific community and the population of the United States based on the\u2026","rel":"","context":"In &quot;Cuba&quot;","block_context":{"text":"Cuba","link":"https:\/\/www.cubasupport.ie\/latest\/category\/cuba\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/www.cubasupport.ie\/latest\/wp-content\/uploads\/cima-vax.jpg?fit=480%2C360&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":6815,"url":"https:\/\/www.cubasupport.ie\/latest\/cuban-vaccine-against-lung-cancer-makes-its-way-into-the-us-video\/","url_meta":{"origin":5661,"position":5},"title":"Cuban vaccine against lung cancer makes its way into the US (+ Video)","author":"Editorial Team","date":"July 20, 2022","format":false,"excerpt":"Collaboration is beneficial for both countries Vaccine against lung cancer\u00a0Photo:\u00a0Prensa Latina The Cuban therapeutic vaccine against lung cancer, Cimavax-EGF, the result of more than two decades of research, with satisfactory results in people with advanced stages of lung cancer, conquers the US scientific community and its population, from the achievements\u2026","rel":"","context":"In &quot;Featured&quot;","block_context":{"text":"Featured","link":"https:\/\/www.cubasupport.ie\/latest\/category\/news\/featured\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/www.cubasupport.ie\/latest\/wp-content\/uploads\/Cimavax-EGF.jpeg?fit=700%2C384&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.cubasupport.ie\/latest\/wp-content\/uploads\/Cimavax-EGF.jpeg?fit=700%2C384&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/www.cubasupport.ie\/latest\/wp-content\/uploads\/Cimavax-EGF.jpeg?fit=700%2C384&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/www.cubasupport.ie\/latest\/wp-content\/uploads\/Cimavax-EGF.jpeg?fit=700%2C384&ssl=1&resize=700%2C400 2x"},"classes":[]}],"jetpack_likes_enabled":true,"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p3xdTY-1tj","jetpack_featured_media_url":"https:\/\/i0.wp.com\/www.cubasupport.ie\/latest\/wp-content\/uploads\/laboratorista-en-Centro-de-Inmunologia-Molecular-CIM-750x563-1-750x536-1.jpeg?fit=750%2C536&ssl=1","_links":{"self":[{"href":"https:\/\/www.cubasupport.ie\/latest\/wp-json\/wp\/v2\/posts\/5661","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cubasupport.ie\/latest\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cubasupport.ie\/latest\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cubasupport.ie\/latest\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cubasupport.ie\/latest\/wp-json\/wp\/v2\/comments?post=5661"}],"version-history":[{"count":0,"href":"https:\/\/www.cubasupport.ie\/latest\/wp-json\/wp\/v2\/posts\/5661\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cubasupport.ie\/latest\/wp-json\/wp\/v2\/media\/5662"}],"wp:attachment":[{"href":"https:\/\/www.cubasupport.ie\/latest\/wp-json\/wp\/v2\/media?parent=5661"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cubasupport.ie\/latest\/wp-json\/wp\/v2\/categories?post=5661"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cubasupport.ie\/latest\/wp-json\/wp\/v2\/tags?post=5661"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}